Literature DB >> 29564996

Timing and predictors of severe rotavirus gastroenteritis among unvaccinated infants in low- and middle-income countries.

J F Gruber1, S Becker-Dreps2, M G Hudgens3, M A Brookhart1, J C Thomas1, M Jonsson Funk1.   

Abstract

Delays in rotavirus vaccine schedule could improve performance in low- and middle-income countries (LMICs). However, delaying the first dose could be detrimental if infants experience severe rotavirus gastroenteritis (RVGE) early in life. Our objective was to describe the timing and predictors of severe RVGE in unvaccinated children in LMICs. We analysed the placebo arms from two clinical trials (cohort 1: NCT00241644; cohort 2: NCT00362648). We estimated the rate, cumulative incidence (per 1000 infants) and age distribution of severe RVGE episodes. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals (CI) for the association between baseline factors and severe RVGE. Cumulative incidence at 6 months of age was 23/1000 (95% CI 15-30) in cohort 1 and 6/1000 (95% CI 3-8) in cohort 2. Early antibiotic use (compared with no use) was associated with 2.03 (95% CI 1.18-3.48) and 1.41 (95% CI 0.80-2.51) times the rate of severe RVGE in cohorts 1 and 2, respectively. The cumulative incidence of severe RVGE was low at 6 months of age, suggesting that a 4-week delay in the vaccination schedule may not result in a large number of severe RVGE episodes prior to vaccine receipt.

Entities:  

Keywords:  Epidemiology; gastroenteritis; immunisation (vaccination); rotavirus

Mesh:

Substances:

Year:  2018        PMID: 29564996      PMCID: PMC5895523          DOI: 10.1017/S0950268818000626

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  34 in total

1.  Meeting of the immunization Strategic Advisory Group of Experts, April 2009--conclusions and recommendations.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-06-05

2.  A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)

Authors:  K Ulm
Journal:  Am J Epidemiol       Date:  1990-02       Impact factor: 4.897

Review 3.  2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; A Duncan Steele; Jazmin Duque; Umesh D Parashar
Journal:  Lancet Infect Dis       Date:  2011-10-24       Impact factor: 25.071

4.  Efficacy of the oral pentavalent rotavirus vaccine in Mali.

Authors:  Samba O Sow; Milagritos Tapia; Fadima C Haidara; Max Ciarlet; Fatoumata Diallo; Mamoudou Kodio; Moussa Doumbia; Rokiatou D Dembélé; Oumou Traoré; Uma U Onwuchekwa; Kristen D C Lewis; John C Victor; A Duncan Steele; Kathleen M Neuzil; Karen L Kotloff; Myron M Levine
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

5.  Heterogeneity of Rotavirus Vaccine Efficacy Among Infants in Developing Countries.

Authors:  Joann F Gruber; Darcy A Hille; G Frank Liu; Susan S Kaplan; Micki Nelson; Michelle G Goveia; T Christopher Mast
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

6.  Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trial.

Authors:  Syed Asad Ali; Abdul Momin Kazi; Margaret M Cortese; Jessica A Fleming; Umesh D Parashar; Baoming Jiang; Monica Malone McNeal; Duncan Steele; Zulfiqar Bhutta; Anita Zaidi
Journal:  J Infect Dis       Date:  2014-06-16       Impact factor: 5.226

7.  Population-based surveillance for severe rotavirus gastroenteritis in children in Karachi, Pakistan.

Authors:  Romena Qazi; Shazia Sultana; Shiyam Sundar; Haider Warraich; Tayyab un-Nisa; Abida Rais; Anita K M Zaidi
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

8.  Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Satoshi Iwata; Shuji Nakata; Susumu Ukae; Yoshitugu Koizumi; Yasuyuki Morita; Haruo Kuroki; Yoshiyuki Tanaka; Toshiyuki Shizuya; Florian Schödel; Michelle L Brown; Jody Lawrence
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

9.  Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial.

Authors:  Andrew Duncan Steele; Kathleen M Neuzil; Nigel A Cunliffe; Shabir A Madhi; Pieter Bos; Bagrey Ngwira; Desiree Witte; Stacy Todd; Cheryl Louw; Mari Kirsten; Sanet Aspinall; Leen Jan Van Doorn; Alain Bouckenooghe; Pemmaraju V Suryakiran; Htay Htay Han
Journal:  BMC Infect Dis       Date:  2012-09-13       Impact factor: 3.090

10.  Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination.

Authors:  A Duncan Steele; Shabir A Madhi; Nigel A Cunliffe; Timo Vesikari; Kong Boo Phua; Fong Seng Lim; E Anthony S Nelson; Yu-Lung Lau; Li-Min Huang; Naveen Karkada; Serge Debrus; Htay Htay Han; Bernd Benninghoff
Journal:  Hum Vaccin Immunother       Date:  2016-06-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.